<a href="https://www.fiercebiotech.com/medtech/jjs-ottava-surgical-robot-meets-primary-endpoints-gastric-bypass-study" hreflang="en">J&J’s Ottava surgical robot meets primary endpoints in gastric bypass study</a>
Johnson & Johnson's Ottava surgical robot successfully met primary safety and performance endpoints in a clinical study for gastric bypass surgery, demonstrating its capability to perform the procedure entirely robotically. The company plans to use these results to support its FDA application for de novo approval for various upper abdominal surgeries.
Johnson & Johnson's Ottava surgical robot achieving primary endpoints in its clinical study for gastric bypass is a significant milestone, suggesting strong potential for FDA de novo approval. This advancement not only positions Ottava as a competitor to existing robotic systems like Intuitive Surgical's da Vinci but also demonstrates an innovative design that allows for integration into smaller operating rooms. This could expand robotic surgery accessibility and adoption, highlighting a potential area for investment or collaboration in the evolving robotic surgery market.